

Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry.
This journal is © The Royal Society of Chemistry 2025

Supporting Information

Photodriven, TFA-promoted Oxidative Dehydrogenative Coupling of Quinoxalin-2(*1H*)-ones with 5-Pyrazolones

Peipei Ma,^a Junyu Wang,^a Hongli Wu,^a Haifeng Gan,^{*a} Fei Cao^a and Jianliang Zhu

^a College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing, 211816, P. R. Of China

E-mail: ganhaifeng@njtech.edu.cn


Table of Contents

1. General information.....	3
2. Synthesis of substrates.....	3-4
3. Synthesis of product.....	4
4. The mechanistic studies.....	4-8
5. Characterization data of the products.....	8-22
6. References.....	22-23
7. Copies of NMR spectra of the products.....	24-71

1. General Information

All reactions were conducted on a sealed tub. NMR spectra were recorded on a Bruker spectrometer. ^1H NMR spectra were obtained at 400 MHz, 500 MHz or 600 MHz in CDCl_3 ($\delta = 7.26$ ppm) or $\text{DMSO}-d_6$ ($\delta = 2.50$ ppm). Coupling constants are given in Hz. ^{13}C NMR spectra were recorded at 101 MHz, 126 MHz or at 151 MHz in CDCl_3 ($\delta = 77.0$ ppm) or $\text{DMSO}-d_6$ ($\delta = 39.50$ ppm). ^{19}F NMR spectra were obtained at 376 MHz in CDCl_3 . Chemical shifts are given in δ ppm and are measured relative to tetramethylsilane (TMS) as internal standard. The peak patterns are indicated as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; qui, quintet; sxt, sextet. High-resolution mass measurement was performed with an electrospray ionization (ESI) or electron ionization (EI) method on a Q-TOF mass spectrometer operating in positive ion mode. Melting point (mp) was measured on a microscopic melting point apparatus. Flash column chromatography was carried out using commercially available 200-300 mesh under pressure unless otherwise indicated. All other starting materials and solvents were commercially available and were used without further purification unless otherwise stated.


2. General procedure for the synthesis of Quinoxalinones^[1] and Pyrazolone^[2]



2.1 To a stirred solution of 1,2-phenylenediamines (10 mmol, 1.0 equiv.) in EtOH (40 mL) was added ethyl glyoxalate (12 mmol, 1.2 equiv.). After addition, the resultant reaction mixture was stirred at 85 °C/rt until the raw material disappears. The solid formed was filtered, washed with water/EtOH and dried in vacuo to obtain the product quinoxalin-2(*1H*)-one. For alkylation, the corresponding alkyl halide (1.6 equiv.) was added to a suspension of quinoxalinone (4.0 mmol, 1.0 equiv.) and K_2CO_3 (1.2 equiv.) in DMF (8 mL). The mixture was stirred at room temperature (monitored by TLC). After completion of reaction, saturated solution of NH_4Cl (10 mL) and water (50 mL) were added to the reaction system, extracted with EtOAc (40 mL*3), the combined organic phases were washed with brine (20 mL*2), dried with anhydrous Na_2SO_4 , filtered, evaporated in vacuum and purified by silica gel column chromatography (Petroleum/EtOAc = 10:1-2:1 or $\text{CH}_2\text{Cl}_2/\text{EtOAc}$ = 9:1-4:1) to afford the desired products **1a-1z/4a**.


Note: When the raw material is 4-methylbenzene-1,2-diamine, the targeted products obtained are 6-methyl-substituted and 7-methyl-substituted compounds. Due to their similar polarities, they participate in subsequent reactions as a mixture.

2.2 General Procedure for the synthesis of substituted pyrazolones



To 12 mmol (1.0 equiv.) of β -ketoester in 50 mL of acetic acid, 12 mmol (1.0 equiv.) of substituted hydrazine was added (1.0 equiv. of TEA was added when hydrazine hydrochloride was used). The contents were refluxed for 24 h, then the mixture was cooled, and the solvent was removed in vacuo. To the precipitate in the flask (some crude were purified by flash chromatography on silica gel), ethyl acetate was added to suspend the product, and it was then filtered to obtain the pure compound. The obtained product was dried to yield substituted pyrazolone.

2.3 General Procedure for Obtaining Quinoxalin-2(1*H*) ones **4b-4e**^[3]



A mixture of phenol (4.0 mmol) and K₂CO₃ (1.1 g, 8.0 mmol) in DMF (6.4 mL) was stirred at 55 °C, and then 1,3-dibromopropane (8.0 mmol) was added. After stirring overnight, water was added to the mixture and extracted with dichloromethane (DCM). The organic phase was washed with water (40 mL x 2), then washed with brine (40 mL x 2), dried over Na₂SO₄, followed by concentration and purification on silica gel column chromatography. The resulting compound (1.6 equiv.) was then dissolved in anhydrous DMF (10 mL) and quinoxalin-2(1*H*)-one (1.0 equiv.) was added and the mixture stirred for 12 h at 55 °C. After the reaction was complete, the mixture was quenched with water and extracted with CH₂Cl₂. The combined organic layers were concentrated in vacuo and the residue obtained was purified by flash chromatography on silica gel to obtain the desired product (**4b-4e**).


3. General procedure for the synthesis of 4-quinoxalinone-substituted pyrazoles (**3/5a-5e**)

A mixture of **1a-1z/4a-4e** (0.2 mmol), edaravone and its analogs **2a-2n** (0.24 mmol or 0.3 mmol), CH₃CN (2.0 mL) and TFA (15 μL, 0.2 mmol, 1.0 equiv.) were placed in a sealed tub (25 mL) containing a magnetic stirring bar and stirred irradiated with LED (450-455 nm) at rt for 16 h under air atmosphere. After the reaction was completed (TLC), the mixture were diluted with MeOH (5 mL) and dichloromethane (10 mL), evaporated in vacuum and purified by silica gel column chromatography using petroleum ether and EtOAc as eluent (9:1-3:1) to afford the related products **3/5a-5e** (51-98%).

4. The mechanistic studies

4.1 Controlled experiments

To further elucidate the reaction mechanism, several control experiments were carried out (scheme S1). Conducting the reaction in dry CH₃CN under N₂ conditions, we found that trace **3aa** could be detected which suggested that oxygen in air played a key role in the reaction (scheme 2a 1). Besides, carried out the reaction without light or TFA, **3aa** could be acquired in 69% and 23% yields, respectively (scheme 2a 2 and 3). The results indicate that both light and TFA are important in the transformations. TEMPO (4.0 equiv.) and BHT (4.0 equiv.) are added to the reaction system with **1a** (0.1 mmol) and **2a** (1.5 equiv.) under standard conditions, **3aa** are provided in trace and 93% yields, respectively and adducts **X** and **Y** can be detected by MS (scheme 2b and 2c 1) (Figure S1 and S2). Besides, BHT (4.0 equiv.) are added to the reaction system under standard conditions without light, **3aa** are provided in 9% yield (scheme 2c 2). It showed that radical pathway may be involved in the reactions.



Scheme S1 Controlled experiments




Figure S1 MS spectra of **3aa**-TEMPO adduct (Compound X: MS (ESI) $[M+H]^+ = 490.28$ ($C_{28}H_{36}N_5O_3$))




Figure S2 MS spectra of **2a**-BHT adduct (Compound Y: MS (ESI) $[M+H]^+ = 393.23$ ($C_{25}H_{33}N_2O_2$))

4.2 EPR Spectra




Figure S3 EPR OF DMPO captured O_2^- in 5-20 min Simulated EPR of DMPO captured $ROO\cdot/O_2^-$ under standard reaction conditions

EPR was measured under standard conditions (5 min-20 min). Superoxide anion radicals (O_2^-) can be detected in 10 min and it fades in 20 min.

4.3 In-situ 1H NMR analyses

4.3.1 To three sample bottles charged **2a** (17.5 mg, 0.1 mmol) and chloroform-*d* (600 μ L) was added CF_3COOH (none), CF_3COOH (3.8 μ L, 0.05 mmol), CF_3COOH (7.5 μ L, 0.1 mmol), respectively. Then, all the samples were subjected to the NMR test. The chemical shift of **2a** appeared at 7.855 ppm (d, 2H), when 0.5 equiv. and 1.0 equiv. TFA were added into **2a** solution, new peaks appeared at 5.527 ppm (s, 0.79 H) and 5.595 ppm (s, 3.28 H) respectively, indicating existence of tautomerization (Figure S4) (28% and 62% of **2a'** appeared at NMR spectra, see copies of NMR spectra at page 24-25).




Figure S4 1H NMR spectra of **2a** and **2a** + CF_3COOH in $CDCl_3$.

4.3.2 1H NMR used tetramethylsilane as the internal standard. The units of chemical shift (δ) and coupling constant (J) were ppm and Hz, respectively. To three sample bottles charged **1a** (16.0 mg, 0.1 mmol) and chloroform-*d* (600 μ L) was added CF_3COOH (none), CF_3COOH (3.8 μ L, 0.05 mmol), CF_3COOH (7.5 μ L, 0.1 mmol), respectively. Then, all the samples were subjected to the NMR test.




Figure S5 ^1H NMR spectra of **1a** and **1a** + CF_3COOH in CDCl_3

The chemical shift of **1a** appeared at 8.304 ppm, when 0.5 equiv. and 1 equiv. TFA were added into **1a** solution, the chemical shift changed to 8.348 ppm and 8.400 ppm respectively, indicating existence of protonation (Figure S5).

4.4 Photophysical properties: UV/Vis absorption spectra

4.4.1 The UV/Vis absorption spectra of **1a** and **1a** + CF_3COOH in acetonitrile (0.1 M) were determined in a 1 cm optical program quartz colorimetric dish. The tail absorption of **1a** with system concentration showed at 425 nm, which redshifts to 470 nm when CF_3COOH was added (Figure S6).




Figure S6 Absorption spectra of **1a** and **1a** + CF_3COOH in acetonitrile at the concentration of the system reaction

4.4.2 The UV/Vis absorption spectra of **2a** and **2a** + CF_3COOH in acetonitrile (0.1 M) were determined in a 1 cm optical program quartz colorimetric dish. The tail absorption of **2a** with system concentration showed at 308 nm, which enhances to 324 nm and then drops when CF_3COOH was added (Figure S7).





Figure S7 Absorption spectra of **2a** and **2a** + CF₃COOH in acetonitrile at the concentration of the system reaction


5. Characterization data of the products

3-(5-Hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (**3aa**)




Orange solid (98%, 65 mg); Silica gel column chromatography (PE/EA = 9:2); ¹H NMR (500 MHz, CDCl₃) δ 15.08 (s, 1H), 7.89 (d, *J* = 8.0 Hz, 2H), 7.49 (d, *J* = 7.4 Hz, 1H), 7.39 (t, *J* = 7.8 Hz, 2H), 7.31 – 7.28 (m, 1H), 7.26 – 7.22 (m, 1H), 7.21 – 7.16 (m, 2H), 3.62 (s, 3H), 2.61 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 155.03, 149.33, 145.74, 138.41, 129.47, 128.66, 127.20, 125.19, 124.68, 120.25, 113.99, 98.81, 29.79, 18.97. HRMS (ESI) *m/z* calcd for C₁₉H₁₇N₄O₂ [M+H]⁺ 333.1346, found 333.1345.

3-(5-Hydroxy-3-methyl-1-(*p*-tolyl)-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (**3ab**)




Orange solid (92%, 64 mg); Silica gel column chromatography (PE/EA = 6:1-2:1); ¹H NMR (500 MHz, CDCl₃) δ 14.98 (s, 1H), 7.76 (d, *J* = 8.2 Hz, 2H), 7.55 (d, *J* = 7.4 Hz, 1H), 7.34 (t, *J* = 7.5 Hz, 1H), 7.27 (d, *J* = 9.8 Hz, 1H), 7.21 (t, *J* = 8.2 Hz, 3H), 3.67 (s, 3H), 2.63 (s, 3H), 2.36 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 155.24, 149.28, 146.10, 141.36, 140.34, 135.97, 135.06, 129.57, 129.25, 127.28, 124.73, 120.55, 114.00, 98.88, 29.85, 20.95, 18.85. HRMS (ESI) *m/z* calcd for C₂₀H₁₉N₄O₂ [M+H]⁺ 347.1503, found 347.1505.

3-(5-Hydroxy-1-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (**3ac**)




Orange solid (81%, 59 mg); Silica gel column chromatography (PE/EA = 4:1-2:1); ^1H NMR (500 MHz, CDCl_3) δ 14.88 (s, 1H), 7.76 (d, J = 8.9 Hz, 2H), 7.54 (d, J = 7.7 Hz, 1H), 7.34 (t, J = 7.6 Hz, 1H), 7.27 (t, J = 7.5 Hz, 1H), 7.21 (d, J = 8.2 Hz, 1H), 6.93 (d, J = 9.0 Hz, 2H), 3.82 (s, 3H), 3.66 (s, 3H), 2.62 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 157.32, 155.22, 149.19, 146.25, 131.72, 129.53, 127.31, 124.70, 122.29, 113.97, 113.87, 98.71, 55.41, 29.82, 18.74. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{19}\text{N}_4\text{O}_3$ $[\text{M}+\text{H}]^+$ 363.1413, found 363.1415.

3-(1-(4-Fluorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (3ad)




Orange solid (89%, 62 mg); Silica gel column chromatography (PE/EA = 5:1-3:1); ^1H NMR (500 MHz, CDCl_3) δ 15.06 (s, 1H), 7.86 (dd, J = 7.8, 5.9 Hz, 2H), 7.51 (d, J = 7.4 Hz, 1H), 7.34 (t, J = 7.5 Hz, 1H), 7.27 (t, J = 7.4 Hz, 1H), 7.21 (d, J = 8.2 Hz, 1H), 7.07 (t, J = 8.6 Hz, 2H), 3.66 (s, 3H), 2.61 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 161.08, 159.14, 155.02, 149.40, 145.71, 134.58, 129.50, 127.28, 124.75, 122.65 (d, J = 8.1 Hz), 121.90 (d, J = 4.7 Hz), 115.34 (d, J = 22.6 Hz), 114.03, 98.70, 29.85, 18.96; ^{19}F NMR (376 MHz, CDCl_3) δ -115.07, -117.01. HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{16}\text{FN}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 350.1250, found 350.1252.

3-(1-(4-Chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (3ae)



Orange solid (85%, 62 mg); Silica gel column chromatography (PE/EA = 6:1-2:1); ^1H NMR (500 MHz, CDCl_3) δ 15.08 (s, 1H), 7.84 (d, J = 8.8 Hz, 2H), 7.46 (d, J = 7.0 Hz, 1H), 7.35 – 7.22 (m, 4H), 7.17 (d, J = 8.2 Hz, 1H), 3.61 (s, 3H), 2.59 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 154.81, 149.47, 145.15, 137.05, 130.00, 129.45, 128.59, 127.13, 124.71, 120.77, 114.05, 98.70, 29.83, 19.17. HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{16}\text{ClN}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 367.0943, found 367.0945.


3-(1-(4-Bromophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (3af)



Orange solid (83%, 68 mg); Silica gel column chromatography (PE/EA = 6:1-2:1); ^1H NMR (500 MHz, CDCl_3) δ 15.15 (s, 1H), 7.85 (d, J = 8.7 Hz, 2H), 7.53 (t, J = 8.3 Hz, 1H), 7.47 (d, J = 8.7 Hz, 2H), 7.38 (t, J = 7.6 Hz, 1H), 7.31 (t, J = 7.5 Hz, 1H), 7.28 – 7.25 (m, 1H), 3.70 (s, 3H), 2.65 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 155.05, 149.68, 148.81, 137.59, 131.87, 131.68, 129.58, 127.29, 124.84, 122.18,


121.38, 118.06, 114.16, 98.91, 29.95, 19.17. HRMS (ESI) m/z calcd for $C_{19}H_{16}BrN_4O_2$ $[M+H]^+$ 411.0457, found 411.0445.

3-(5-Hydroxy-3-methyl-1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (3ag)




Orange solid (73%, 59 mg); Silica gel column chromatography (PE/EA = 6:1-2:1); 1H NMR (500 MHz, $CDCl_3$) δ 15.25 (s, 1H), 8.12 (d, J = 8.0 Hz, 2H), 7.62 (d, J = 8.2 Hz, 2H), 7.53 (d, J = 3.0 Hz, 1H), 7.37 (t, J = 7.2 Hz, 1H), 7.32-7.24 (m, 2H), 3.69 (s, 3H), 2.67 (s, 3H); ^{19}F NMR (376 MHz, $CDCl_3$) δ -62.07. HRMS (ESI) m/z calcd for $C_{20}H_{16}F_3N_4O_2$ $[M+H]^+$ 401.1220, found 401.1227.

3-(5-Hydroxy-3-methyl-1-(*m*-tolyl)-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (3ah)




Orange solid (93%, 64 mg); Silica gel column chromatography (PE/EA = 6:1-2:1); 1H NMR (500 MHz, $CDCl_3$) δ 15.06 (s, 1H), 7.72 (d, J = 6.6 Hz, 2H), 7.53 (d, J = 7.6 Hz, 1H), 7.36 – 7.26 (m, 3H), 7.21 (d, J = 8.2 Hz, 1H), 7.03 (d, J = 7.4 Hz, 1H), 3.66 (s, 3H), 2.64 (s, 3H), 2.41 (s, 3H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 155.09, 149.29, 145.88, 138.59, 138.27, 129.49, 128.49, 127.21, 126.13, 124.69, 120.97, 117.55, 114.00, 98.83, 29.81, 21.53, 18.93. HRMS (ESI) m/z calcd for $C_{20}H_{19}N_4O_2$ $[M+H]^+$ 347.1503, found 347.1507.

3-(1-(3,4-Dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (3ai)




Orange solid (92%, 66 mg); Silica gel column chromatography (PE/EA = 7:1-2:1); 1H NMR (500 MHz, $CDCl_3$) δ 14.98 (s, 1H), 7.63 (s, 1H), 7.60 (d, J = 8.1 Hz, 1H), 7.52 (d, J = 7.6 Hz, 1H), 7.32 (t, J = 7.6 Hz, 1H), 7.26 (t, J = 7.5 Hz, 1H), 7.19 (d, J = 8.2 Hz, 1H), 7.14 (d, J = 8.1 Hz, 1H), 3.64 (s, 3H), 2.62 (s, 3H), 2.30 (s, 3H), 2.26 (s, 3H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 155.17, 149.17, 146.08, 136.94, 136.15, 133.77, 129.69, 129.51, 127.22, 124.65, 121.73, 118.07, 113.94, 98.82, 29.78, 19.89, 19.23, 18.81. HRMS (ESI) m/z calcd for $C_{21}H_{21}N_4O_2$ $[M+H]^+$ 361.1659, found 361.1655.

3-(1-(3-Chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl)-1-ethylquinoxalin-2(1H)-one (CAS: 3061317-16-3) (3bj)^[4]




Orange solid (88%, 67 mg); Silica gel column chromatography (PE/EA = 5:1-2:1); ^1H NMR (500 MHz, CDCl_3) δ 15.23 (s, 1H), 7.96 (s, 1H), 7.87 (d, J = 8.2 Hz, 1H), 7.49 (d, J = 5.4 Hz, 1H), 7.32 (t, J = 7.6 Hz, 1H), 7.28-7.21 (m, 3H), 7.11 (d, J = 7.9 Hz, 1H), 4.26 (q, J = 7.1 Hz, 2H), 2.63 (s, 3H), 1.39 (t, J = 7.2 Hz, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 154.34, 149.59, 145.39, 143.04, 139.51, 134.30, 129.60, 128.31, 127.21, 124.69, 124.54, 119.54, 117.44, 113.87, 109.97, 102.58, 98.67, 38.26, 19.17, 12.19. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{18}\text{ClN}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 381.1113, found 381.1115.

3-(1-(2-Chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (3ak)




Orange solid (96%, 70 mg); Silica gel column chromatography (PE/EA = 4:1-3:1); ^1H NMR (500 MHz, CDCl_3) δ 14.74 (s, 1H), 7.59 – 7.48 (m, 3H), 7.41 – 7.34 (m, 3H), 7.31-7.26 (m, 2H), 3.70 (s, 3H), 2.67 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 160.45, 155.31, 150.08, 146.71, 135.24, 132.14, 130.20, 129.77, 129.55, 129.46, 127.57, 127.33, 124.78, 113.99, 97.78, 29.85, 18.64. HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{16}\text{ClN}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 367.0943, found 367.0940.

3-(5-Hydroxy-1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (3al)




Yellow solid (97%, 75 mg); Silica gel column chromatography (PE/EA = 7:1-3:1); ^1H NMR (500 MHz, CDCl_3) δ 14.43 (s, 1H), 7.90 – 7.80 (m, 3H), 7.53 (t, J = 7.7 Hz, 1H), 7.49-7.42 (m, 3H), 7.38-7.34 (m, 2H), 3.81 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 161.55, 160.76, 155.57 (d, J = 41.8 Hz), 145.95, 140.56 (q, J = 3.7 Hz), 137.67, 133.35, 130.38, 129.84, 129.24, 128.97, 127.37, 125.44, 122.45, 120.12, 113.99, 99.21, 30.15; ^{19}F NMR (376 MHz, CDCl_3) δ -62.35. HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{14}\text{F}_3\text{N}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 386.1020, found 386.1025.

3-(1-Benzyl-5-hydroxy-3-methyl-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (3am)




Yellow solid (68%, 47 mg); Silica gel column chromatography (PE/EA = 4:1-3:1); ^1H NMR (500 MHz, CDCl_3) δ 14.30 (s, 1H), 7.61 (d, J = 7.9 Hz, 1H), 7.38 – 7.21 (m, 8H), 5.09 (s, 2H), 3.67 (s, 3H), 2.57 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 157.67, 155.63, 149.04, 147.68, 141.84, 136.96, 131.58, 129.62, 128.49, 127.65, 127.42, 126.06, 124.73, 113.83, 97.98, 49.61, 29.76, 18.16. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{19}\text{N}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 347.1503, found 347.1508.

3-(5-Hydroxy-1,3-dimethyl-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (CAS: 3061317-32-3) (3an)^[4]




Yellow solid (88%, 48 mg); Silica gel column chromatography (PE/EA = 4:1-2:1); ¹H NMR (500 MHz, CDCl₃) δ 14.07 (s, 1H), 7.58 (d, *J* = 7.8 Hz, 1H), 7.35 (t, *J* = 7.3 Hz, 1H), 7.28 (t, *J* = 7.3 Hz, 1H), 7.22 (d, *J* = 8.3 Hz, 1H), 3.66 (s, 3H), 3.51 (s, 3H), 2.50 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 157.09, 155.57, 148.63, 147.78, 131.89, 129.58, 127.59, 126.38, 124.63, 113.72, 97.69, 32.61, 29.71, 17.92. HRMS (ESI) *m/z* calcd for C₁₄H₁₅N₄O₂ [M+H]⁺ 271.1190, found 271.1191.

1-Ethyl-3-(5-hydroxy-3-methyl-1H-pyrazol-4-yl)quinoxalin-2(1H)-one (CAS: 3061317-19-6) (3bo)^[4]




Yellow solid (72%, 39 mg); Silica gel column chromatography (PE/EA = 3:2); ¹H NMR (500 MHz, DMSO) δ 7.72 (d, *J* = 8.0 Hz, 1H), 7.64 (d, *J* = 8.4 Hz, 1H), 7.54 (t, *J* = 7.8 Hz, 1H), 7.39 (t, *J* = 7.6 Hz, 1H), 4.34 (q, *J* = 7.0 Hz, 2H), 2.51 (d, *J* = 8.3 Hz, 3H), 1.28 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 159.35, 154.85, 149.90, 144.47, 133.41, 129.12, 128.90, 128.32, 124.44, 114.66, 99.61, 37.92, 14.98, 12.17. HRMS (ESI) *m/z* calcd for C₁₄H₁₅N₄O₂ [M+H]⁺ 271.1190, found 271.1189.

1-Ethyl-3-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)quinoxalin-2(1H)-one (CAS: 3061317-11-8) (3ba)^[4]




Orange solid (93%, 64 mg); Silica gel column chromatography (PE/EA = 7:1-4:1); ¹H NMR (500 MHz, CDCl₃) δ 15.12 (s, 1H), 7.91 (d, *J* = 7.9 Hz, 2H), 7.56 (d, *J* = 7.4 Hz, 1H), 7.40 (t, *J* = 7.9 Hz, 2H), 7.34 (t, *J* = 7.7 Hz, 1H), 7.28-7.24 (m, 2H), 7.20 (t, *J* = 7.4 Hz, 1H), 4.29 (q, *J* = 7.1 Hz, 2H), 2.66 (s, 3H), 1.38 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 161.11, 154.68, 149.45, 146.19, 138.43, 128.66, 128.40, 127.33, 125.25, 124.57, 120.42, 113.84, 98.86, 38.22, 18.86, 12.20. HRMS (ESI) *m/z* calcd for C₂₀H₁₉N₄O₂ [M+H]⁺ 347.1503, found 347.1505.

3-(5-Hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-propylquinoxalin-2(1H)-one (3ca)




Orange solid (96%, 69 mg); Silica gel column chromatography (PE/EA = 6:1); ^1H NMR (500 MHz, CDCl_3) δ 15.12 (s, 1H), 7.92 (d, J = 7.8 Hz, 2H), 7.59 (d, J = 7.0 Hz, 1H), 7.42 (t, J = 8.0 Hz, 2H), 7.37 (t, J = 7.8 Hz, 1H), 7.33 – 7.25 (m, 2H), 7.22 (t, J = 7.4 Hz, 1H), 4.28 – 4.15 (m, 2H), 2.68 (s, 3H), 1.89 – 1.75 (m, 2H), 1.07 (t, J = 7.4 Hz, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 155.04, 149.55, 146.50, 138.46, 128.78, 128.72, 127.35, 125.38, 124.62, 120.61, 114.09, 98.99, 44.65, 20.46, 18.87, 11.27. HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{21}\text{N}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 361.1659, found 361.1654.

1-Allyl-3-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)quinoxalin-2(1H)-one (3da)




Orange solid (97%, 70 mg); Silica gel column chromatography (PE/EA = 6:1); ^1H NMR (500 MHz, CDCl_3) δ 15.08 (s, 1H), 7.93 (d, J = 7.9 Hz, 2H), 7.61 (d, J = 6.3 Hz, 1H), 7.44-7.41 (m, 2H), 7.36 (t, J = 7.3 Hz, 1H), 7.31 (t, J = 7.2 Hz, 1H), 7.27 (d, J = 7.6 Hz, 1H), 7.22 (t, J = 7.4 Hz, 1H), 6.00-5.92 (m, 1H), 5.32 (d, J = 10.4 Hz, 1H), 5.23 (d, J = 17.3 Hz, 1H), 4.93 (d, J = 5.0 Hz, 2H), 2.69 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 154.99, 149.52, 146.20, 138.43, 130.08, 128.85, 128.77, 127.27, 125.45, 124.82, 120.63, 118.50, 114.67, 99.11, 45.32, 18.94. HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{19}\text{N}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 359.1508, found 359.1511.

3-(5-Hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-(prop-2-yn-1-yl)quinoxalin-2(1H)-one (3ea)



Orange solid (88%, 63 mg); Silica gel column chromatography (PE/EA = 6:1-3:1); ^1H NMR (500 MHz, CDCl_3) δ 15.01 (s, 1H), 7.93 (d, J = 7.8 Hz, 2H), 7.57 (d, J = 7.4 Hz, 1H), 7.42 (t, J = 8.0 Hz, 4H), 7.33 (t, J = 7.3 Hz, 1H), 7.22 (t, J = 7.4 Hz, 1H), 5.05 (d, J = 2.3 Hz, 2H), 2.69 (s, 3H), 2.34 (t, J = 2.5 Hz, 1H); ^{13}C NMR (126 MHz, CDCl_3) δ 154.46, 149.25, 145.24, 138.36, 128.79, 128.09, 127.13, 125.41, 125.13, 120.40, 114.63, 99.18, 73.67, 32.35, 29.67, 19.14. HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{17}\text{N}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 357.1346, found 357.1344.


1-Butyl-3-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)quinoxalin-2(1H)-one (3fa)



Orange solid (91%, 68 mg); Silica gel column chromatography (PE/EA = 6:1); ^1H NMR (500 MHz, CDCl_3) δ 14.94 (s, 1H), 7.92 (d, J = 8.0 Hz, 2H), 7.61 (d, J = 6.5 Hz, 1H), 7.46 – 7.35 (m, 3H), 7.33 – 7.26 (m, 2H), 7.22 (t, J = 7.4 Hz, 1H), 4.26 (t, J = 7.0 Hz, 2H), 2.68 (s, 3H), 1.83 – 1.70 (m, 2H), 1.57 – 1.44 (m, 2H), 1.02 (t, J = 7.3 Hz, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 155.02, 149.64, 146.49, 138.39,


133.77, 128.80, 128.73, 127.43, 125.46, 124.63, 120.71, 116.67, 114.07, 99.00, 43.02, 29.11, 20.19, 18.78, 13.70. HRMS (ESI) m/z calcd for $C_{22}H_{23}N_4O_2$ $[M+H]^+$ 375.1743, found 375.1751.

***tert*-Butyl 2-(3-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-2-oxoquinoxalin-1(2H)-yl)acetate (3ga)**




Orange solid (85%, 58 mg); Silica gel column chromatography (PE/EA = 7:1-4:1); 1H NMR (500 MHz, $CDCl_3$) δ 14.98 (s, 1H), 7.93 (d, J = 7.8 Hz, 2H), 7.57 (d, J = 7.4 Hz, 1H), 7.42 (t, J = 8.0 Hz, 2H), 7.35-7.28 (m, 2H), 7.22 (t, J = 7.4 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 4.92 (s, 2H), 2.67 (s, 3H), 1.48 (s, 9H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 165.61, 155.04, 149.26, 145.33, 138.35, 128.86, 128.76, 127.14, 125.38, 124.93, 120.45, 118.81, 113.59, 99.11, 83.49, 44.87, 27.96, 19.04. HRMS (ESI) m/z calcd for $C_{24}H_{25}N_4O_4$ $[M+H]^+$ 433.1850, found 433.1855.

3-(5-Hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)quinoxalin-2(1H)-one (3ha)




Orange solid (95%, 61 mg); The reaction mixture was filtered, washed with EtOAc and dried under vacuum; 1H NMR (500 MHz, DMSO) δ 15.40 (s, 1H), 12.97 (s, 1H), 7.88 (d, J = 7.7 Hz, 2H), 7.65 (d, J = 7.8 Hz, 1H), 7.45 (t, J = 7.9 Hz, 2H), 7.41 (t, J = 7.6 Hz, 1H), 7.36 – 7.29 (m, 2H), 7.24 (t, J = 7.4 Hz, 1H), 2.56 (s, 3H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 159.59, 155.76, 148.64, 147.64, 138.24, 128.82, 128.21, 127.63, 125.22, 124.53, 123.19, 119.87, 115.61, 98.27, 18.51. HRMS (ESI) m/z calcd for $C_{18}H_{15}N_4O_2$ $[M+H]^+$ 319.1190, found 319.1197.

1-Benzyl-3-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)quinoxalin-2(1H)-one (3ia)




Orange solid (94%, 77 mg); Silica gel column chromatography (PE/EA = 7:1-4:1); 1H NMR (500 MHz, $CDCl_3$) δ 15.05 (s, 1H), 7.95 (d, J = 7.9 Hz, 2H), 7.58 (s, 1H), 7.43 (t, J = 8.0 Hz, 2H), 7.34 (t, J = 7.3 Hz, 2H), 7.30-7.20 (m, 7H), 5.51 (s, 2H), 2.70 (s, 3H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 155.46, 149.52, 146.04, 138.42, 134.55, 129.01, 128.94, 128.75, 127.86, 127.28, 126.67, 125.40, 124.82, 120.54, 114.91, 99.18, 46.64, 18.99. HRMS (ESI) m/z calcd for $C_{18}H_{15}N_4O_2$ $[M+H]^+$ 319.1190, found 319.1197.

3-(5-Hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-(4-methylbenzyl)quinoxalin-2(1H)-one (3ja)




Orange solid (97%, 82 mg); Silica gel column chromatography (PE/EA = 7:1-3:1); ^1H NMR (500 MHz, CDCl_3) δ 15.01 (s, 1H), 7.94 (d, $J = 7.9$ Hz, 2H), 7.59 (s, 1H), 7.43 (t, $J = 8.0$ Hz, 2H), 7.30 – 7.22 (m, 4H), 7.18 – 7.12 (m, 4H), 5.47 (s, 2H), 2.71 (s, 3H), 2.31 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 155.46, 149.57, 146.25, 138.41, 137.65, 136.44, 131.52, 130.38, 129.66, 128.99, 128.75, 127.30, 126.70, 125.43, 124.78, 120.62, 114.95, 99.18, 46.44, 21.03, 18.95. HRMS (ESI) m/z calcd for $\text{C}_{26}\text{H}_{23}\text{N}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 422.1743, found 422.1751.

1-(4-Fluorobenzyl)-3-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)quinoxalin-2(1H)-one (3ka)




Orange solid (87%, 74 mg); Silica gel column chromatography (PE/EA = 6:1-3:1); ^1H NMR (500 MHz, CDCl_3) δ 15.01 (s, 1H), 7.93 (d, $J = 7.9$ Hz, 2H), 7.59 (s, 1H), 7.43 (t, $J = 7.9$ Hz, 2H), 7.31 – 7.20 (m, 6H), 7.03 (t, $J = 8.6$ Hz, 2H), 5.46 (s, 2H), 2.69 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 163.28, 161.31, 155.45, 149.50, 138.38, 130.34 (d, $J = 3.2$ Hz), 128.78, 128.62 (d, $J = 8.2$ Hz), 127.31, 125.47, 124.96, 120.56, 116.00 (d, $J = 9.2$ Hz), 114.70, 99.21, 46.00, 19.00; ^{19}F NMR (376 MHz, CDCl_3) δ -113.84. HRMS (ESI) m/z calcd for $\text{C}_{25}\text{H}_{20}\text{FN}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 426.1550, found 426.1554.

1-(4-Chlorobenzyl)-3-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)quinoxalin-2(1H)-one (3la)




Orange solid (81%, 72 mg); Silica gel column chromatography (PE/EA = 6:1-3:1); ^1H NMR (500 MHz, CDCl_3) δ 14.94 (s, 1H), 7.93 (d, $J = 8.0$ Hz, 2H), 7.58 (s, 1H), 7.42 (t, $J = 7.9$ Hz, 2H), 7.33 – 7.26 (m, 4H), 7.24 – 7.14 (m, 4H), 5.45 (s, 2H), 2.68 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 155.42, 149.46, 138.37, 133.83, 133.09, 129.21, 128.77, 128.72, 128.17, 127.31, 125.45, 124.99, 120.53, 114.66, 99.21, 46.04, 19.00. HRMS (ESI) m/z calcd for $\text{C}_{25}\text{H}_{20}\text{ClN}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 443.1241, found 443.1244.

1-(4-Bromobenzyl)-3-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)quinoxalin-2(1H)-one (3ma)




Orange solid (86%, 84 mg); Silica gel column chromatography (PE/EA = 7:1-4:1); ^1H NMR (500 MHz, CDCl_3) δ 14.98 (s, 1H), 7.93 (d, J = 7.9 Hz, 2H), 7.56 (d, J = 3.0 Hz, 1H), 7.48 – 7.39 (m, 4H), 7.28-7.21 (m, 3H), 7.13 (t, J = 7.2 Hz, 3H), 5.41 (s, 2H), 2.68 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 155.38, 149.43, 138.36, 133.62, 132.14, 128.75, 128.68, 128.46, 127.28, 125.41, 124.97, 121.84, 120.46, 114.64, 99.18, 46.07, 19.01. HRMS (ESI) m/z calcd for $\text{C}_{25}\text{H}_{20}\text{BrN}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 487.0764, found 487.0769.

3-(5-Hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-(4-(trifluoromethyl)benzyl)quinoxalin-2(1H)-one (3na)




Yellow solid (82%, 78 mg); Silica gel column chromatography (PE/EA = 7:1-3:1); ^1H NMR (500 MHz, CDCl_3) δ 15.01 (s, 1H), 7.93 (d, J = 8.0 Hz, 2H), 7.60 (d, J = 8.2 Hz, 3H), 7.42 (t, J = 7.9 Hz, 2H), 7.36 (d, J = 8.1 Hz, 2H), 7.31 – 7.21 (m, 3H), 7.12 (d, J = 7.7 Hz, 1H), 5.54 (s, 2H), 2.68 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 155.45, 150.05, 149.44, 138.49 (d, J = 35.8 Hz), 130.31 (q, J = 32.8 Hz), 128.79, 128.67, 127.36, 127.01, 126.05 (d, J = 3.4 Hz), 125.49, 125.11, 124.91, 122.74, 120.52, 114.56, 99.25, 46.25, 19.01; ^{19}F NMR (376 MHz, CDCl_3) δ -62.69. HRMS (ESI) m/z calcd for $\text{C}_{26}\text{H}_{19}\text{F}_3\text{N}_4\text{O}_2\text{Na}$ $[\text{M}+\text{Na}]^+$ 499.1352, found 499.1370.

3-(5-Hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-(3-methylbenzyl)quinoxalin-2(1H)-one (3oa)




Orange solid (97%, 82 mg); Silica gel column chromatography (PE/EA = 7:1); ^1H NMR (500 MHz, CDCl_3) δ 15.11 (s, 1H), 7.95 (d, J = 8.0 Hz, 2H), 7.57 (s, 1H), 7.43 (t, J = 7.9 Hz, 2H), 7.26 – 7.18 (m, 5H), 7.09 (d, J = 7.6 Hz, 1H), 7.03 (d, J = 11.8 Hz, 2H), 5.45 (s, 2H), 2.70 (s, 3H), 2.31 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 155.42, 149.50, 146.06, 138.80, 138.43, 134.79, 134.48, 128.97, 128.84, 128.71, 128.61, 127.19, 125.34, 124.75, 123.65, 120.48, 114.95, 99.15, 46.63, 21.36, 18.98. HRMS (ESI) m/z calcd for $\text{C}_{26}\text{H}_{23}\text{N}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 422.1743, found 422.1746.

3-(5-Hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-(3-methoxybenzyl)quinoxalin-2(1H)-one (3pa)




Orange solid (83%, 73 mg), Silica gel column chromatography (PE/EA = 6:1-2:1); ^1H NMR (500 MHz, CDCl_3) δ 15.09 (s, 1H), 7.95 (d, J = 8.0 Hz, 2H), 7.59 (s, 1H), 7.43 (t, J = 7.9 Hz, 2H), 7.29 – 7.21 (m, 5H), 6.85 – 6.77 (m, 3H), 5.48 (s, 2H), 3.76 (s, 3H), 2.70 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 160.10, 155.45, 149.53, 138.41, 136.14, 130.10, 128.96, 128.76, 127.31, 125.42, 124.84, 120.58, 118.82, 114.94, 112.88, 112.71, 99.18, 55.20, 46.58, 18.98. HRMS (ESI) m/z calcd for $\text{C}_{26}\text{H}_{23}\text{N}_4\text{O}_3$ $[\text{M}+\text{H}]^+$ 439.1765, found 439.1771.

1-(2-Chlorobenzyl)-3-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)quinoxalin-2(1H)-one (3qa)




Yellow solid (85%, 75 mg), Silica gel column chromatography (PE/EA = 7:1-4:1); ^1H NMR (500 MHz, CDCl_3) δ 14.94 (s, 1H), 7.93 (d, J = 7.9 Hz, 2H), 7.58 (d, J = 6.5 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.41 (t, J = 8.0 Hz, 2H), 7.29-7.20 (m, 4H), 7.14 (t, J = 7.5 Hz, 1H), 6.99 (d, J = 7.9 Hz, 1H), 6.82 (d, J = 7.7 Hz, 1H), 5.57 (s, 2H), 2.68 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 155.47, 149.40, 145.62, 138.37, 132.61, 131.61, 129.88, 129.00, 128.75, 128.60, 127.38, 126.56, 125.39, 125.03, 120.42, 114.79, 99.21, 44.44, 19.05. HRMS (ESI) m/z calcd for $\text{C}_{25}\text{H}_{20}\text{ClN}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 443.1241, found 443.1237.

6-Chloro-3-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (3ra)




Yellow solid (69% yield, 51 mg), Silica gel column chromatography (PE/EA = 7:1-3:1); ^1H NMR (500 MHz, CDCl_3) δ 14.74 (s, 1H), 7.84 (d, J = 7.9 Hz, 2H), 7.55 (s, 1H), 7.39 (t, J = 7.9 Hz, 2H), 7.26 – 7.18 (m, 2H), 7.09 (d, J = 8.9 Hz, 1H), 3.62 (s, 3H), 2.58 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 155.22, 149.94, 146.56, 138.25, 133.53, 130.33, 128.71, 128.24, 127.47, 125.59, 120.62, 115.04, 99.34, 30.03, 18.61. HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{16}\text{ClN}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 367.0962, found 367.0948.

3-(5-Hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-methyl-6-(trifluoromethyl)quinoxalin-2(1H)-one (3sa)




Yellow solid (51%, 41 mg); Silica gel column chromatography (PE/EA = 7:1-3:1); ^1H NMR (500 MHz, CDCl_3) δ 14.60 (s, 1H), 7.91-7.86 (m, 3H), 7.61 (d, J = 6.0 Hz, 1H), 7.48 – 7.33 (m, 3H), 7.26-7.22 (m, 1H), 3.75 (d, J = 4.4 Hz, 3H), 2.66 (s, 3H); ^{19}F NMR (376 MHz, CDCl_3) δ -62.16. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{16}\text{F}_3\text{N}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 401.1219, found 401.1224.

7-Chloro-3-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (3ta)




Yellow solid (56%, 41 mg); Silica gel column chromatography (PE/EA = 8:1-4:1); ^1H NMR (500 MHz, CDCl_3) δ 14.71 (s, 1H), 7.81 (t, J = 7.3 Hz, 2H), 7.44 (s, 1H), 7.41 – 7.34 (m, 2H), 7.28 (s, 1H), 7.20 (t, J = 7.3 Hz, 2H), 7.14 (s, 1H), 6.97 (s, 1H), 3.56 (s, 3H), 2.57 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 177.08, 155.19, 149.69, 147.19, 138.23, 138.09, 133.21, 131.18, 130.35, 128.71, 125.47, 125.05, 120.40, 114.08, 112.77, 99.74, 99.04, 29.96, 18.66. HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{16}\text{ClN}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 367.0962, found 367.0956.

3-(5-Hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1,6,7-trimethylquinoxalin-2(1H)-one (3ua)




Orange solid (76%, 55 mg); Silica gel column chromatography (PE/EA = 6:1-3:1); ^1H NMR (400 MHz, CDCl_3) δ 14.99 (s, 1H), 7.93 (d, J = 7.8 Hz, 2H), 7.43 (t, J = 7.1 Hz, 2H), 7.37 (s, 1H), 7.22 (t, J = 7.4 Hz, 1H), 7.05 (s, 1H), 3.72 (s, 3H), 2.68 (s, 3H), 2.36 (s, 3H), 2.32 (s, 3H). HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{21}\text{N}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 361.1659, found 361.1657.

6,7-Difluoro-3-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (3va)




Orange solid (76%, 55 mg); Silica gel column chromatography (PE/EA = 8:1-3:1); ^1H NMR (600 MHz, CDCl_3) δ 14.35 (s, 1H), 7.83 (d, J = 7.7 Hz, 2H), 7.56 (t, J = 9.0 Hz, 1H), 7.44 (t, J = 8.0 Hz, 2H), 7.28 – 7.26 (m, 1H), 7.14 (dd, J = 11.0, 7.0 Hz, 1H), 3.74 (s, 3H), 2.63 (s, 3H); ^{19}F NMR (376 MHz, CDCl_3) δ -132.73, -132.90, -133.12, -139.92 (d, J = 23.7 Hz). HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{14}\text{F}_2\text{N}_4\text{O}_2$ $[\text{M}]^+$ 368.1085, found 368.1087.

6,7-Dichloro-3-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (3wa)




Orange solid (81%, 65 mg); Silica gel column chromatography (PE/EA = 8:1-3:1); ^1H NMR (600 MHz, CDCl_3) δ 14.50 (s, 1H), 7.82 (d, J = 7.9 Hz, 2H), 7.74 (s, 1H), 7.42 (t, J = 7.8 Hz, 2H), 7.33 (s, 1H), 7.24 (d, J = 7.4 Hz, 1H), 3.68 (s, 3H), 2.62 (s, 3H). HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{15}\text{Cl}_2\text{N}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 401.0571, found 401.0566.

6,7-Dibromo-3-(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-methylquinoxalin-2(1H)-one (3xa)




Orange solid (65%, 63 mg); Silica gel column chromatography (PE/EA = 9:1-3:1); ^1H NMR (600 MHz, CDCl_3) δ 14.56 (s, 1H), 7.88 (s, 1H), 7.82 (d, J = 7.8 Hz, 2H), 7.49 (s, 1H), 7.44 – 7.38 (m, 2H), 7.24 (t, J = 7.4 Hz, 1H), 3.66 (s, 3H), 2.61 (s, 3H). HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{16}\text{Br}_2\text{N}_4\text{O}_2$ $[\text{M}+2]^+$ 490.9562, found 490.9535.

3-(5-Hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-methylbenzo[g]quinoxalin-2(1H)-one (3ya)




Orange solid (65%, 63 mg); Silica gel column chromatography (PE/EA = 6:1-3:1); ^1H NMR (600 MHz, CDCl_3) δ 15.42 (s, 1H), 7.97 (s, 2H), 7.91 (s, 1H), 7.85 (d, J = 7.3 Hz, 2H), 7.58 (s, 1H), 7.53 – 7.46 (m, 2H), 7.44 (t, J = 7.9 Hz, 2H), 7.22 (t, J = 7.3 Hz, 1H), 3.80 (s, 3H), 2.71 (s, 3H). HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{19}\text{N}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 383.1508, found 383.1512.

3-(5-Hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1-phenylquinoxalin-2(1H)-one (3za)




Orange solid (84%, 66 mg); Silica gel column chromatography (PE/EA = 6:1-4:1); ^1H NMR (500 MHz, CDCl_3) δ 13.64 (s, 1H), 7.94 (d, J = 7.6 Hz, 2H), 7.67-7.59 (m, 4H), 7.44 – 7.13 (m, 8H), 6.58 (d, J = 8.2 Hz, 1H), 2.66 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 155.17, 149.36, 138.37, 135.65, 130.66, 130.47, 129.77, 128.73, 128.07, 126.72, 125.32, 124.89, 120.41, 115.93, 99.24, 77.25, 77.00, 76.75, 19.16. HRMS (ESI) m/z calcd for $\text{C}_{24}\text{H}_{19}\text{N}_4\text{NaO}_2$ $[\text{M}+\text{Na}]^+$ 417.1322, found 417.1322.

3-(2-Oxoquinoxalin-1(2H)-yl)propyl 2-acetoxybenzoate (4a, CAS: 3056011-80-1)^[3c]




Light yellow oil. ^1H NMR (600 MHz, CDCl_3) δ 8.30 (s, 1H), 8.00 (dd, $J = 7.8, 1.4$ Hz, 1H), 7.89 (d, $J = 8.0$ Hz, 1H), 7.61–7.55 (m, 2H), 7.38–7.33 (m, 3H), 7.13 (d, $J = 8.1$ Hz, 1H), 4.47 – 4.38 (m, 4H), 2.34 (s, 3H), 2.27 – 2.21 (m, 2H). HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{19}\text{N}_2\text{O}_5$ $[\text{M}+\text{H}]^+$ 367.1288, found 367.1292.

3-(2-Oxoquinoxalin-1(2H)-yl)propyl 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoate (4b, CAS: 3067017-81-3)^[3d,e]




Light yellow oil; Silica gel column chromatography (PE/EA = 5:1–4:1); ^1H NMR (500 MHz, CDCl_3) δ 8.30 (s, 1H), 7.90 (d, $J = 8.2$ Hz, 1H), 7.56 (t, $J = 7.2$ Hz, 1H), 7.35 (d, $J = 7.9$ Hz, 2H), 6.96 (d, $J = 7.4$ Hz, 1H), 6.66 – 6.58 (m, 2H), 4.36 – 4.30 (m, 2H), 4.22 (t, $J = 6.1$ Hz, 2H), 3.94 (t, $J = 6.6$ Hz, 2H), 2.29 (s, 3H), 2.16 – 2.09 (m, 5H), 1.76 (d, $J = 2.9$ Hz, 4H), 1.26 (s, 6H). HRMS (ESI) m/z calcd for $\text{C}_{26}\text{H}_{32}\text{N}_2\text{O}_4$ $[\text{M}]^+$ 436.2362, found 436.2356.

3-(2-Oxoquinoxalin-1(2H)-yl)propyl 2-(4-isobutylphenyl)propanoate (4c, CAS: 2647904-18-3)^[3a]



Light yellow oil; Silica gel column chromatography (PE/EA = 4:1–3:1); ^1H NMR (500 MHz, CDCl_3) δ 8.27 (s, 1H), 7.87 (d, $J = 8.0$ Hz, 1H), 7.45 (t, $J = 7.2$ Hz, 1H), 7.33 (t, $J = 7.6$ Hz, 1H), 7.24 (d, $J = 8.0$ Hz, 2H), 7.11 (d, $J = 8.0$ Hz, 2H), 7.07 (d, $J = 8.4$ Hz, 1H), 4.27–4.22 (m, 1H), 4.20 – 4.14 (m, 3H), 3.73 (q, $J = 7.1$ Hz, 1H), 2.41 (d, $J = 7.2$ Hz, 2H), 2.07 – 2.00 (m, 2H), 1.83–1.74 (m, 1H), 1.52 (d, $J = 7.2$ Hz, 3H), 0.83 (dd, $J = 6.6, 1.6$ Hz, 6H). HRMS (ESI) m/z calcd for $\text{C}_{24}\text{H}_{29}\text{N}_2\text{O}_3$ $[\text{M}+\text{H}]^+$ 393.2156, found 393.2159.


3-Methoxy-4-(3-(2-oxoquinoxalin-1(2H)-yl)propoxy)benzaldehyde (4d, CAS: 2414081-19-7)^[3b]



Light yellow solid. ^1H NMR (600 MHz, CDCl_3) δ 9.86 (s, 1H), 8.30 (s, 1H), 7.90 (d, $J = 8.0$ Hz, 1H), 7.62 (d, $J = 8.4$ Hz, 1H), 7.53 (t, $J = 7.8$ Hz, 1H), 7.43 (dd, $J = 5.5, 1.7$ Hz, 2H), 7.35 (t, $J = 7.6$ Hz,


1H), 6.94 (d, $J = 8.6$ Hz, 1H), 4.52 (t, $J = 7.2$ Hz, 2H), 4.21 (t, $J = 5.8$ Hz, 2H), 3.95 (s, 3H), 2.41 – 2.34 (m, 2H). HRMS (ESI) m/z calcd for $C_{19}H_{17}N_2O_4$ $[M-H]^-$ 337.1315, found 337.1319.

3-(3-(5-Hydroxy-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)-2-oxoquinoxalin-1(2*H*)-yl)propyl 2-acetoxybenzoate (5a, CAS: 3061317-60-3, from Aspirin and Edaravone)^[4]




Orange oil (91%, 98 mg); Silica gel column chromatography (PE/EA = 4:1-3:1); 1H NMR (500 MHz, $CDCl_3$) δ 14.98 (s, 1H), 7.96 (d, $J = 7.8$ Hz, 1H), 7.91 (d, $J = 8.0$ Hz, 2H), 7.54 (dd, $J = 12.3, 4.6$ Hz, 2H), 7.42 (t, $J = 7.9$ Hz, 2H), 7.37 – 7.32 (m, 1H), 7.32 – 7.27 (m, 3H), 7.21 (t, $J = 7.4$ Hz, 1H), 7.09 (d, $J = 8.0$ Hz, 1H), 4.44 (dd, $J = 11.9, 6.2$ Hz, 4H), 2.65 (s, 3H), 2.32 – 2.21 (m, 5H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 169.53, 164.14, 155.14, 150.65, 149.44, 138.40, 134.04, 131.37, 128.74, 128.54, 127.41, 125.96, 125.39, 124.79, 123.75, 122.94, 120.53, 113.83, 98.92, 62.62, 40.45, 26.42, 20.90, 18.94. HRMS (ESI) m/z calcd for $C_{30}H_{27}N_4O_6$ $[M+H]^+$ 539.1925, found 539.1918.

3-(3-(5-Hydroxy-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)-2-oxoquinoxalin-1(2*H*)-yl)propyl 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoate (5b, from Gemfibrozil and Edaravone)



Orange oil (97%, 118 mg); Silica gel column chromatography (PE/EA = 7:1-6:1); 1H NMR (500 MHz, $CDCl_3$) δ 14.11 (s, 1H), 7.92 (d, $J = 7.8$ Hz, 2H), 7.57 (d, $J = 6.9$ Hz, 1H), 7.41 (t, $J = 7.9$ Hz, 2H), 7.36 – 7.18 (m, 4H), 6.96 (d, $J = 7.4$ Hz, 1H), 6.65 – 6.57 (m, 2H), 4.29 (t, $J = 7.4$ Hz, 2H), 4.22 (t, $J = 6.0$ Hz, 2H), 3.94 (s, 2H), 2.66 (s, 3H), 2.29 (s, 3H), 2.15 (s, 3H), 2.14-2.08 (m, 2H), 1.78 (s, 4H), 1.29 (s, 6H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 177.38, 156.72, 154.85, 149.37, 145.81, 138.29, 136.30, 130.14, 128.60, 128.46, 127.28, 125.23, 124.66, 123.33, 120.62, 120.31, 113.57, 111.84, 98.84, 67.85, 61.59, 42.04, 40.36, 37.01, 26.42, 25.06, 21.25, 18.79, 15.63. HRMS (ESI) m/z calcd for $C_{36}H_{41}N_4O_5$ $[M+H]^+$ 609.3136, found 609.3118.


3-(3-(5-Hydroxy-3-methyl-1-phenyl-1*H*-pyrazol-4-yl)-2-oxoquinoxalin-1(2*H*)-yl)propyl 2-(4-isobutylphenyl)propanoate (5c, from Ibuprofen and Edaravone)



Orange solid (95%, 107 mg); Silica gel column chromatography (PE/EA = 6:1-5:1); 1H NMR (500 MHz, $CDCl_3$) δ 15.01 (s, 1H), 7.92 (d, $J = 7.9$ Hz, 2H), 7.57 (d, $J = 5.4$ Hz, 1H), 7.41 (t, $J = 7.9$ Hz, 2H), 7.30 – 7.19 (m, 5H), 7.12 (d, $J = 8.0$ Hz, 2H), 7.01 (d, $J = 7.9$ Hz, 1H), 4.26 (dt, $J = 11.6, 5.8$ Hz,

1H), 4.22 – 4.13 (m, 3H), 3.74 (q, $J = 7.1$ Hz, 1H), 2.66 (s, 3H), 2.42 (d, $J = 7.2$ Hz, 2H), 2.10 – 2.01 (m, 2H), 1.84-1.76 (m, 1H), 1.53 (d, $J = 7.2$ Hz, 3H), 0.85 (dd, $J = 6.6, 1.5$ Hz, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 174.39, 154.99, 149.45, 144.88, 140.68, 138.38, 137.60, 129.42, 128.70, 128.54, 127.37, 127.08, 125.36, 124.67, 120.50, 113.74, 98.92, 61.85, 45.13, 44.94, 40.22, 30.06, 26.29, 22.26, 18.86, 18.28. HRMS (ESI) m/z calcd for $\text{C}_{34}\text{H}_{37}\text{N}_4\text{O}_4$ $[\text{M}+\text{H}]^+$ 565.2815, found 565.2824.

4-(3-(3-(5-Hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-2-oxoquinoxalin-1(2H)-yl)propoxy)-3-methoxybenzaldehyde (5d, from Vanillin and Edaravone)



Light yellow solid (72%, 73 mg); Silica gel column chromatography (DCM/MeOH = 500:1-300:1); ^1H NMR (500 MHz, CDCl_3) δ 15.05 (s, 1H), 9.84 (s, 1H), 7.91 (d, $J = 7.9$ Hz, 2H), 7.60 (dd, $J = 20.5, 5.5$ Hz, 2H), 7.44-7.39 (m, 4H), 7.37 – 7.29 (m, 2H), 7.22 (t, $J = 7.4$ Hz, 1H), 6.93 (d, $J = 8.1$ Hz, 1H), 4.57 (t, $J = 7.0$ Hz, 2H), 4.24 (t, $J = 5.5$ Hz, 2H), 3.90 (s, 3H), 2.64 (s, 3H), 2.44 – 2.36 (m, 2H); ^{13}C NMR (126 MHz, CDCl_3) δ 190.77, 155.39, 153.39, 149.84, 138.40, 130.46, 128.85, 128.79, 127.46, 126.60, 125.51, 124.85, 120.68, 114.31, 111.57, 109.21, 98.92, 66.34, 55.86, 40.54, 26.96, 18.88. HRMS (ESI) m/z calcd for $\text{C}_{29}\text{H}_{25}\text{N}_4\text{O}_5$ $[\text{M}-\text{H}]^-$ 509.1910, found 509.1915.

5. References

- [1] a) K. Zheng, K. Liang, J. Zhu, H. Chen, P. Zhang, C. Shen and J. Cao, Self-catalytic photochemical three-component reaction for the synthesis of multifunctional 3,3-disubstituted oxindoles, *Mol. Catal.*, 2024, **565**, 114379; b) W. Zhao, Y. Zhang, S. Yuan, X. Yu, L. Liu and J. Li, Direct Alkylation of Quinoxalinones with Boracene-Based Alkylborate under Visible Light Irradiation, *J. Org. Chem.*, 2023, **88**, 6218-6226; c) S. Cao, J.-X. Chen, X.-L. Zhang, X. Song, W.-Y. Song, Y.-S. Wu, Y.-H. Zhang and Z. Liu, Merging Quinoxalin-2(1H)-ones Excitation with Cobaloxime Catalysis: C3 Alkylation of Quinoxalin-2(1H)-ones with Unactivated Alkyl Iodides and Carboxylic Acids under Light, *Org. Lett.*, 2024, **26**, 5833-5838; d) Singh, S. R. Nasireddy, G. C. Upreti, S. Arora and A. Singh, Photocatalytic, Intermolecular Olefin Alkylcarbofunctionalization Triggered by Haloalkyl Radicals Generated via Halogen Atom Transfer, *Org. Lett.*, 2023, **25**, 5558-5562; e) N. Yadav, A. K. Sahoo, D. Sarkar and J. N. Moorthy, Metal-free Generation of Halogen Radicals Using NXs/TBHP: Application in Site-Selective Halogenation of Quinoxalin-2(1H)-Ones and Synthesis of Gem-Dihaloketones, *ChemRxiv*, 2024, 1-12; f) Liu, Y. Huang, F.-L. Qing and X.-H. Xu, Transition-Metal-Free Decarboxylation of 3,3,3-Trifluoro-2,2-dimethylpropanoic Acid for the Preparation of C(CF₃)Me₂-Containing Heteroarenes, *Org. Lett.*, 2018, **20**, 5497-5501. g) S. Song, X. Peng, B. Zhou, L. Zheng, J. Sun, Z. Chen, and J. Li, Acid-Promoted Self-Photocatalyzed Regioselective Oxidation: A Novel Strategy for Accessing Quinoxaline-2,3-diones, *Chem. Eur. J.*, 2024, **30**, e202402848.
- [2] a) Y. Yuan, L.-S. Li, L. Zhang, F. Wang, L. Jiang, L. Zuo, Q. Wang, J.-G. Hu and A. Lei, Electrochemical synthesis of versatile ammonium oxides under metal catalyst-, exogenous-oxidant-, and exogenous-electrolyte-free conditions, *Chem. Commun.*, 2021, **57**, 2768-2771; b) M. Li, S. Yang, J. Zhang, Z. Gao, L. Zheng, F. Lu and Y. Feng, Electrochemical oxidative selective halogenation of pyrazolones for the synthesis of 4-halopyrazolones, *Org. Biomol. Chem.*, 2024, **22**, 6080-6684; c) F.

- Fang, S. Hu, C. Li, Q. Wang, R. Wang, X. Han, Y. Zhou and H. Liu, Catalytic System-Controlled Divergent Reaction Strategies for the Construction of Diversified Spiropyrazolone Skeletons from Pyrazolidinones and Diazopyrazolones, *Angew. Chem., Int. Ed.*, 2021, **60**, 21327-21333; d) R.-H. Wang, Y.-L. Li, H.-J. He, Y.-C. Xiao and F.-E. Chen, Catalytic Asymmetric Addition of Diorganozinc Reagents to Pyrazole-4,5-Diones and Indoline-2,3-Diones, *Chem. Eur. J.*, 2021, **27**, 4302-4306.
- [3] a) L. Laze, P. Romero, I. Bosque and J. C. Gonzalez-Gomez, Oxidative Coupling of 4-Hydroxycoumarins with Quinoxalin-2(1H)-ones Induced by Visible Light under Aerobic Conditions, *Eur. J. Org. Chem.*, 2023, **26**, e202201484; b) Y. Yang, Z. Wei, A. T. Teichmann, F. H. Wieland, A. Wang, X. Lei, Y. Zhu, J. Yin, T. Fan, L. Zhou, C. Wang and L. Chen, Development of a novel nitric oxide (NO) production inhibitor with potential therapeutic effect on chronic inflammation, *Eur. J. Med. Chem.*, 2020, **193**, 112216; c) X.-K. He, J. Lu, A.-J. Zhang, Q.-Q. Zhang, G.-Y. Xu and J. Xuan, BI-OAc-Accelerated C3-H Alkylation of Quinoxalin-2(1H)-ones under Visible-Light Irradiation, *Org. Lett.*, 2020, **22**, 5984-5989; d) E. Falk, A. Franchino, T. Horak, L. Gürtler and B. Morandi, Azide-Free Synthesis of N-Alkyliminophosphoranes from Phosphines and Hydroxylamine Derivatives, *Org. Lett.*, 2023, **25**, 1695-1700; (e) A. Kumar Ghosh, A. Mondal, S. Neogi, F. Mahato, S. Bhunya, L. Roy, A. Hajra, Copper-Catalyzed Carbogermylation of Electron-Deficient Alkenes via 3,4-Difunctionalization of Quinoxalin-2(1H)-ones: Mechanistic Insights from Computational Studies, *Chem. Eur. J.*, 2025, **31**, e202404186.
- [4] S. Zhang, Z. Zhang, C. Qin, M. Hu, J. Wang, F. Ji and G. Jiang, Electrochemical Oxidative Functionalization of Pyrazolin-5-Ones: Access to 4-Quinoxalinone-Substituted Pyrazoles, *Adv. Synth. Catal.*, 2025, **367**, e202400825.

6. NMR spectra of products

